Work

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.6_suppl.510

Authors: Toni K. Choueiri, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy Ann Dawson, Deborah Jean Lee Wong, Shailender Bhatia, Marihella James, Xinxin Shu, Blanca Homet Moreno, Nageatte Ibrahim, Rodolfo F. Perini, Antoni Ribas, Michael B. Atkins

Institutions: Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, University of Washington, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Seattle Cancer Care Alliance, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602260927

Cites:

Cited by: 6

Related to: 10